An important complication of allo-SCT is GVHD, which commonly affects the skin, liver and digestive tract. Clinical symptoms of GVHD of the digestive tract (GVHD-DT) include excessive diarrhoea, abdominal pain and cramps, nausea and vomiting, gastrointestinal bleeding, dysphagia, and weight loss. Treatment is complicated and regarding nutritional support, only a few guidelines are available. Our aim was to critically appraise the literature on nutritional assessment, nutritional status and nutritional support for patients with GVHD-DT. Evidence shows that GVHD-DT is often associated with malnutrition, protein losing enteropathy, magnesium derangements, and deficiencies of zinc, vitamin B 12 and vitamin D. Limited evidence exists on derangements of magnesium, resting energy expenditure, bone mineral density and pancreatic function, and some beneficial effects of n-3 polyunsaturated fatty acids and pancreatic enzyme replacement therapy. Expert opinions recommend adequate amounts of energy, at least 1.5 g protein/kg body weight, supplied by total parenteral nutrition in cases of severe diarrhoea. When diarrhoea is o500 mL a day, a stepwise oral upgrade diet can be followed. No studies exist on probiotics, prebiotics, dietary fibre and immunonutrition in GVHD-DT patients. Future research should focus on absorption capacity, vitamin and mineral status, and nutritional support strategies.
INTRODUCTION
GVHD of the digestive tract (GVHD-DT) is one of the most challenging complications after allo-SCT for haematological malignancies. Although there are no standard criteria, a diagnosis of GVHD-DT may be established by means of histological findings of epithelial cell apoptosis with or without inflammation, epithelial sloughing and the exclusion of infectious causes. [1] [2] [3] The incidence of GVHD-DT is estimated to be 10-60% of patients with GVHD.
evidence of individual studies (1a/b/c, 2a/b/c, 3a/b, 4 and 5) and the grades of recommendation (A, B, C and D) ( Table 1) . 8 
RESULTS OF THE LITERATURE STUDY
The following paragraphs describe the literature findings and evidence on nutritional status, intestinal failure, nutritional support, micronutrients, immunonutrition and probiotics, prebiotics, and dietary fibre in patients with GVHD. A summary of the available evidence on these topics is displayed in Table 2 .
Nutritional status Disease-related malnutrition is associated with loss of body weight and LBM, and affects morbidity and quality of life. 9 Treatmentrelated toxicities and complications may affect nutritional status in the first year following allo-SCT. In patients with GVHD, diarrhoea, systemic inflammation, dysphagia, abdominal pain and anorexia often deteriorate nutritional status. These symptoms are accompanied by an inadequate energy and nutrient intake. 10 In the literature, follow-up of parameters of nutritional status in allo-SCT and GVHD patients has been described in a number of prospective studies, retrospective analyses and case reports; study populations range from n ¼ 2 to n ¼ 2220.
Two studies showed a deterioration of nutritional status after allo-SCT. 11, 12 A large prospective study of high quality showed allo-SCT patients had a lower LBM index than healthy controls, at 6 and 12 months up to 6 years post transplant. In particular patients with chronic (c)GVHD had a significantly lower LBM index, and steroid treatment was associated with a lower LBM index and a higher body fat mass index. 12 In a small prospective study (n ¼ 47 patients who underwent allo-SCT), around 50% of patients experienced diarrhoea at median of 10 days after allo-SCT; diarrhoea had a profound negative effect on nutritional status and well-being, despite the administration of TPN in the majority of those patients. 11 A few studies investigated nutritional status in patients with GVHD, and looked at differences between subgroups with limited and extensive (or active and inactive) GVHD. 6, 10, [13] [14] [15] The study populations and nutritional parameters were heterogeneous, Nutritional support in GVHD of the digestive tract BS van der Meij et al which makes it hard to draw conclusions on the prevalence of malnutrition in patients with GVHD, and study quality was moderate to poor (most were small retrospective studies). Jacobsohn and colleagues retrospectively observed malnutrition (BMI (body mass index) o21.9) in 43% and severe malnutrition in 14% (defined as BMI o21.9 and 18.5) in 93 patients with cGVHD. Patients with active, ongoing cGVHD had lower BMIs than patients with inactive cGVHD. In this study, symptoms thought to contribute to weight loss, such as odynophagia and oral sensitivity, were not related to weight loss. 13 In a large retrospective review of 192 children and adults 1 year post allo-SCT, nutrition-related problems (weight changes, oral sensitivity, xerostomia and so on.) were more frequent in patients with GVHD than in patients without GVHD. The incidence Nutritional support in GVHD of the digestive tract BS van der Meij et al of weight loss was 33% in patients with extensive cGVHD and 19% in patients with limited cGVHD, but the amount of weight loss per patient was not recorded. Weight gain also occurred, in respectively 28 and 34% of patients with limited and extensive cGVHD. Although this study was relatively large, it only estimated the occurrence of nutrition-related problems and weight loss; differences between patients with GVHD and those without GVHD were not statistically analysed. 10 Lee and colleagues retrospectively found steroid myopathy in 41% of 70 patients with acute (a)GVHD using high-dose steroids. 14 In another small retrospective study in 18 children with extensive cGVHD, nine patients with multi-organ involvement experienced severe weight loss (20.9% of their body weight), and required salvage therapy beyond steroids and CSA. In contrast, patients with one organ system involved experienced a lower decrease in body weight (5% of their body weight). In this study, weight loss preceded clinical symptoms of cGVHD. 15 In a small cross-sectional study, Zauner and colleagues investigated resting energy expenditure (REE) and substrate oxidation in 13 patients with chronic extensive GVHD. Patients' average body weights were significantly lower than the body weights before allo-SCT (difference of B10 kg, Po0.05).
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These typical GVHD symptoms were also described in a case series of two patients with GVHD of both the skin and the digestive tract. Both patients experienced side effects of immunosuppressive treatment and difficulties to reach adequate nutritional intake. They lost 410% of their usual body weight. 6 In summary, small retrospective studies and case series indicate that malnutrition and weight loss frequently occur in patients with GVHD (grade B); malnutrition and weight loss appear to be more severe in patients with extensive GVHD compared with patients with limited GVHD (grade C). GVHD and steroid treatment are associated with a decline in lean body mass (grade C). The prevalence of malnutrition in patients with GVHD-DT, as well as the relationship between weight loss and symptoms, such as diarrhoea and oral sensitivity, require further investigation.
Intestinal failure Diarrhoea and protein-losing enteropathy. Diarrhoea is the main complaint of GVHD-DT, and the aetiology can be multi-factorial. Possible causes of diarrhoea include villous atrophy, mucosal ulceration, secretory dysfunction, osmotic factors, rapid passage, pancreatic insufficiency and side effects of medication. 17 Diarrhoea in patients with GVHD-DT is often green, mucoid and watery, 18 and stool volumes can exceed 2 L a day. 1, 19 This may result in dehydration, loss of electrolytes, protein ('protein-losing enteropathy') and fat, and intolerance to oral and enteral feeding. In GVHD-DT of the upper digestive tract, in particular the stomach, complaints include nausea, vomiting, anorexia and/or food intolerance, but not necessarily include diarrhoea. 4, 20 Small prospective studies and case series in patients after allo-SCT investigated the extent of diarrhoea and protein-losing enteropathy.
In a case series of 40 patients with cGVHD and persistent gastrointestinal (GI) symptoms, moderate diarrhoea (500 mL/day to 1 L/day or 3 to 5 times/day) occurred in 39% of patients and severe diarrhoea (41 L/day or 45 times/day) in 48% of patients with GVHD-DT. 2 Two small prospective studies investigated protein-losing enteropathy by measuring alpha 1-antitrypsin in 24-h stool samples. Papadopoulou and colleagues observed protein-losing enteropathy in 91% of 27 patients with diarrhoea after allo-SCT. In this study, protein-losing enteropathy was more severe in patients with GVHD, compared with other causes of diarrhoea. 11 Others showed that in patients after allo-SCT (n ¼ 25), stool alpha 1-antitrypsin significantly increased in those developing GVHD-DT, whereas in patients not developing GVHD-DT, stool alpha 1-antitrypsin returned to below normal values. 20 In summary, small studies suggest that diarrhoea is prevalent in at least 39% of patients with cGVHD (level C). Protein-losing enteropathy (defined by increased alpha 1-anitrypsin in stool samples) occurs after allo-SCT, especially in patients with GVHD(-DT) (level B).
Maldigestion. Maldigestion caused by liver and exocrine pancreatic insufficiency could also have a role in GVHD-DT. 21 Evidence of GVHD of the pancreas has been found on autopsy and in experimental models of GVHD, [22] [23] [24] but pancreatitis in allo-SCT patients could also be caused by drugs like azathioprine, cyclosporine, glucocorticoids and l-asparaginase. 21 Loss of pancreatic exocrine function leads to poor output of digestive enzymes, such as lipases, proteases and carbohydrases. Symptoms of exocrine pancreatic insufficiency include chronic diarrhoea, steatorrhoea, fatigue, abdominal pain, weight loss and flatulence. 25 Faecal fat excretion above the upper limit of normal has been described in 5-8% 2,26 of patients with GVHD-DT, and in 5% of patients with cGVHD. 10 Overall in patients two years post allo-SCT, the probability of developing steatorrhoea was somewhat lower (3.3%). 27 A number of small retrospective studies and case reports investigated pancreatic function in patients with GVHD-DT. In a retrospective review of 30 long-term survivors of allo-SCT, cGVHD-DT occurred in nine patients (30%), and pancreatic atrophy in five patients (16.7%); GVHD involving the liver and digestive tract occurred significantly more frequent in patients who experienced pancreatic atrophy. 28 Akpek and colleagues described four case reports of patients with a clinical presentation of malabsorption. In these patients, radiologic and endoscopic studies did not show evidence of GVHD-DT, and pancreatic insufficiency was ascribed to chronic pancreatitis. 21 One retrospective analysis in 40 patients with cGVHD showed exocrine pancreatic insufficiency in two out of 15 patients experiencing GI symptoms 41 year after the diagnosis of cGVHD. The authors did not specify their definition of pancreatic insufficiency. 2 Pancreatic enzyme substitution may be indicated when faecal fat excretion exceeds 15 g/day, resulting in steatorrhoea and/or when weight loss is present; 29 several case reports of patients with aGVHD or cGVHD documented good effects of pancreatic enzyme replacement therapy on GI symptoms. 2, 21, 25, 30, 31 Apart from assessment of pancreatic exocrine function, investigation of small intestinal function is pivotal in patients receiving induction chemotherapy and allo-SCT. As the small bowel is by far the largest source of circulating citrulline, this amino acid is thought to be an attractive biomarker of enterocyte function. [32] [33] [34] In a large retrospective study (n ¼ 163), plasma citrulline was determined three times a week around allo-SCT to estimate intestinal damage. The authors found a striking pattern of inflammatory response coinciding with the occurrence of plasma hypocitrullineamia for patients receiving myeloablative conditioning; there was a strong correlation between plasma citrulline and C-reactive protein, and between intestinal damage and the occurrence of bacteremia and acute lung injury, but not between plasma citrulline and aGVHD after allo-SCT. 35 The authors also compared the plasma citrulline assay with sugar permeability tests in ten patients receiving myeloablative therapy, and showed plasma citrulline earlier detects maximum intestinal damage as well as recovery of the intestinal damage than sugar permeability tests. 36 Yet, no studies on plasma citrulline in patients with GVHD have been published. In summary, these small studies show that pancreatic atrophy may occur after allo-SCT, especially in patients with GVHD-DT (grade C), and so does exocrine pancreatic insuffiency in patients with GVHD(-DT) (grade C). Pancreatic enzyme replacement therapy may decrease GI symptoms in patients with aGVHD or cGVHD (grade D). Citrulline may be a good biomarker of enterocyte function in allo-SCT patients, but future studies on the significance of citrulline in patients with GVHD are required (grade C).
Nutritional support
Route of administration. Side effects of chemotherapy and complications around SCT can induce nutrition-related symptoms such as nausea, mucositis and anorexia. These symptoms can significantly decrease the ability to tolerate oral nutrition and to meet nutritional needs. 37 Nutritional support by enteral or parenteral nutrition is therefore essential around SCT. Because of severe mucositis, bleeding risks and excessive vomiting, TPN is often applied in clinical patients. However, there is a debate about whether enteral nutrition should be favoured over TPN. 38, 39 The enteral route, if tolerable and clinically possible, may be preferred for maintaining digestive function and mucosal barrier, and prevents bacterial translocation from the digestive tract. 40 In two small non-randomized studies, patients who received enteral nutrition around allo-SCT less often developed aGVHD than those who received parenteral nutrition, and they showed better outcomes in terms of survival. 41, 42 Patients with GVHD-DT often do not tolerate oral or enteral nutrition. In the acute phase with severe diarrhoea (41 L/day), nil by mouth during days to weeks (or even months) is required to alleviate gastrointestinal complaints, and nutritional support consists of TPN. When the volume of diarrhoea has decreased (typically to o500 mL/day), oral food is restarted, but certain foods may be better tolerated than others. 19, 37, 43 General guidelines of the Seattle Cancer Care Alliance recommend specific upgrade diets for patients with GVHD-DT, with limited amounts of fats, fibre, lactose, acidic items and GI irritants, which are stepwise introduced. 19 Only one prospective study investigated effects of this stepwise upgrade diet in 18 patients with GVHD-DT; in this study, the stepwise upgrade diet was compared with a historic control cohort (n ¼ 17) receiving nil by mouth and TPN, for effects. In the stepwise upgrade diet group, there was a significantly slower decrease of laboratory parameters (serum total protein and albumin; Po0.001). Changes in body weight were not significantly different between groups. The oral diet appeared to be safely applicable to patients suffering from GVHD-DT, and recovery to a normal diet tended to be shorter (31 vs 38 days, P ¼ 0.09) in the stepwise upgrade diet group. This study was limited by the small sample size, comparison with a historic control group, and the definition of recovery to a normal diet was unclear. 17 In brief, guidelines recommend TPN and nil by mouth in patients with 4500 mL of diarrhoea (level D). With regard to the introduction and type of oral nutrition in patients with GVHD-DT, the oral upgrade diet appears to be safe (level C). More research on nutritional support in patients with GVHD-DT is required.
Energy requirements. Weight loss in patients with GVHD-DT could hypothetically be a consequence of increased REE. In many disease states, REE is not markedly different from the predicted REE, between 100-107%. 44 However, some diseases, in particular sepsis, trauma and burns, cause a clinically relevant increase in REE of 40 to 80%. 44 In cachectic cancer patients, REE is elevated in some patients and decreased in other patients. 45 It is generally suggested that energy requirements during the early phase of SCT are 50-70% above REE. 46, 47 In theory, patients with active cGVHD can be in a hyper metabolic state for months or even years. This hyper metabolic state is likely a response to inflammatory cytokines (TNF-a, IL-1 and IL-6) or alterations in levels of norepinephrine and glucagon. 15, 16 One small cross-sectional study compared REE by indirect calorimetry of 13 patients with chronic extensive GVHD of the skin, mucocutaneous membranes, lung, eyes and liver, with REE of healthy age-, sex-, height-and weight-matched controls, and showed a small increase in REE (1.9 kcal/kg/day or 133 kcal in a person of 70 kg) and alterations in fat and carbohydrate oxidation rates. The effects of glucocorticoids and CYA on energy metabolism were not investigated in this study, although these drugs could modify energy metabolism. Probably, this study was too small and patients too heterogenous to draw conclusions on REE. In addition, physical activity level, body composition and use of medication was not documented. 16 It is expected that energy expenditure in patients with GVHD-DT is increased, but apparently little is known about this topic. Thus, grade C evidence suggests small, clinically irrelevant, increases in REE in patients with chronic extensive GVHD, but more research is required.
Protein requirements. The World Health Organization states that the accepted safe value for intake of protein is 0.83 g/kg body weight/ day for healthy subjects of both sexes, all ages and all body weights (within the acceptable range). 48 The maximum capacity of protein synthesis on whole body level is reached with a protein intake of 1.5 g/kg/day in healthy volunteers as well as in critically ill patients. 9 Patients with GVHD-DT probably have increased protein requirements, but human studies on this topic have not been performed until now. Chronic use of high-dose of corticosteroids contributes to an increased need for protein. 6 In addition, GVHD-DT patients lose protein by mucosal exudation because of an abnormal or inflamed mucosal surface.
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Expert opinions and reviews (level D) on nutritional support in SCT recommend 1.8-2.5 g/kg/day in case of malnutrition and severe complications (that is, GVHD), and 1.5-1.8 g/kg/day if no severe malnutrition and only mild complications are present. 43, 47 Micronutrients As patients with GVHD-DT experience nutritional and metabolic derangements, requirements for micronutrients might alter, and so does micronutrient status. Due to diarrhoea, malabsorption and inadequate food intake, GVHD-DT patients are at high risk of being in a deficient state for electrolytes and vitamins. In the literature, vitamin D, B 12 , zinc, magnesium and iron have been discussed in relationship with allo-SCT and GVHD.
Vitamin D. Reduced bone mineral density is a well-known complication of SCT and probably relates to treatment with steroids and/or vitamin D deficiencies.
Four small (n ¼ 9 to n ¼ 79) studies in various study populations described the occurrence of vitamin D deficiency and/or bone loss after allo-SCT. In a cross-sectional study in 79 long-term (43 years) survivors of allo-SCT, bone loss occurred in 73.4% of patients. The risk of bone loss was higher in older patients, but was independent of sex, treatment, diagnosis, TBI and GVHD. 50 One small prospective study in patients with cGVHD who were treated with corticosteroids and CYA showed that six out of eight patients had a decrease in bone mineral density one year after transplantation. These patients also had low serum levels of 1.25-dihydroxycholecalciferol (1.25(OH) 2 D 3 ). 51 Two other prospective studies investigated vitamin D status after allo-SCT. A study in 67 children who had been treated for cGVHD found a high percentage of vitamin D deficiency or insufficiency (80.6%). This means that there could be a deficiency in transforming vitamin D 3 in the liver or in the kidneys.
In summary, these studies provide fair evidence for the occurrence of vitamin D deficiencies in patients with GVHD (grade B), and for the occurrence of bone loss after allo-SCT, in particular in patients with GVHD (grade C). In general, treatment of reduced bone mineral density consists of supplementation of calcium and vitamin D, in combination with biphosphonates. Supplementation of the active metabolites 1.25(OH) 2 D 3 or 25(OH) 3 could result in a superior effect on bone density and contribute to modulation of GVHD. 54, 55 Vitamin B 12 . Regarding water-soluble vitamins, only vitamin B 12 has been discussed in the literature. GVHD of the stomach affects the production of intrinsic factor, and GVHD of the small intestinal mucosa produces long-term impairment of vitamin B 12 absorption. 25 One small prospective study in 26 patients found a severely reduced absorption of vitamin B 12 shortly after allo-BMT, which was ascribed to the effects of the conditioning regime, resulting in crypt cell degeneration. Vitamin B 12 further decreased in six patients with cGVHD, of which only two patients had obvious clinical symptoms of GVHD-DT. Probably, bowel function was also impaired in those with GVHD involving other sites. 56 Monitoring vitamin B 12 status appears necessary in patients with GVHD (grade C).
Zinc. Zinc requirements may also change in cases of GVHD-DT, as chronic diarrhoea and malabsorption may lead to faecal losses of zinc and zinc deficiencies. Zinc has an important role in wound healing and taste acuity, and is important for maintaining the integrity of mucosal defence against intestinal infection. 57, 58 In clinical practice, zinc status is measured by plasma zinc and alkaline phosphatase, but the gold standard is to assess zinc concentrations in hair or in tissue, such as liver or blood cells.
Only one prospective study documented zinc deficiency in 67% of 47 children following BMT, especially in those with diarrhoea (grade C).
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Dysgeusia (abnormal taste or taste alterations) is a common side effect of cancer treatment (radiotherapy and/or chemotherapy) and may be prevented or treated by zinc supplementation, but so far, the evidence on supplementation of zinc in general cancer patients is limited. [59] [60] [61] Although the evidence is limited, expert opinions recommend to supply increased zinc (and vitamin C) for patients with GVHD, following the requirements of patients with wounds (grade D). 6 Other expert opinions suggest supplementation of zinc (up to 3 times daily 45 mg ZnSO 4 ) is safe and effective to improve taste disorders in cancer patients (grade D). 59 Trace elements. Only a few publications on minerals and trace elements (magnesium and iron) have been found in GVHD. Grade C evidence suggests magnesium derangements in patients using immunosuppressive medication; common side effects are hypomagnesaemia, but there have also been several case reports of GVHD patients that endured hypermagnesaemia. A magnesiumcontaining cathartic and a magnesium-containing antacid seemed to be the cause. Both led to a rapid rise in serum magnesium, possibly due to an increased permeability of the inflamed digestive tract and dehydration. 60, 61 Finally, iron overload is common in SCT patients. 62 Causes include enhanced iron absorption due to anaemia, and multiple blood transfusions before and after allo-SCT. Allo-SCT may contribute to the dysregulation of iron homoeostasis by way of hepatic and intestinal injury due to GVHD. According to case series, iron overload appears to be less prevalent among Auto-SCT patients compared with allo-SCT patients. 62 Iron may also increase the risk of GVHD through its tendency to cause direct organ toxicity; alternatively, it might decrease the risk of GVHD through its ability to impair host immune responses. 63 Therefore, expert opinions recommend using iron-free multivitamin/mineral supplements in patients with GVHD. 6 Immunonutrition Immunonutrition is a special form of enteral nutrition containing specific nutrients. The most commonly used and researched are n-3 fatty acids, glutamine, arginine and nucleotides. Targets for immunonutrition are mucosal barrier function, cellular defence and local or systemic inflammation.
N-3 polyunsaturated fatty acids. N-3 polyunsaturated fatty acids downregulate the inflammatory response by suppressing the production of inflammatory cytokines and vascular endothelial damage, and by improving overall immune function. The n-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid produce beneficial effects through alterations in membrane structure and function, and gene transcription. Gamma-linolenic acid, the essential n-3 polyunsaturated fatty acid, appears to act additively with eicosapentaenoic acid and docosahexaenoic acid in decreasing acute inflammation and organ injury. 64 Meta-analyses showed favourable effects of an enteral nutrition containing a high concentration of n-3 fatty acids on mortality, secondary infections and length of hospital stay in ICU patients with sepsis, acute respiratory distress syndrome and systemic inflammation response syndrome. 64 Systemic inflammation response syndrome has also been linked to the aetiology of GVHD, 65, 66 and grade C evidence suggests beneficial effects of eicosapentaenoic acid: in a small prospective study, supplementation of eicosapentaenoic acid around BMT was associated with a reduction of inflammatory cytokines (IL-10, TNF-a and IFN-g), reduced vascular endothelial dysfunction, higher survival rate 67 and a lower grade of acute colonic GVHD. 68 Glutamine, arginine and nucleotides. The nonessential amino acid glutamine is a precursor for nucleotide synthesis; rapidly dividing cells, such as enterocytes, are most likely to suffer from a shortage of glutamine. During stress and trauma, endogenous production of glutamine may become insufficient, while consumption of glutamine by lymphocytes and enterocytes is increased. In experimental and clinical studies, supplementation of glutamine has been demonstrated to restore the integrity of the gastrointestinal mucosa and decrease bacterial translocation during cancer treatment. 64 Glutamine not only modulates the immune system's function in the digestive tract but may also promote intestinal healing and reduce the severity of mucositis and GVHD. 69 However, clinical studies on enteral or parenteral supplementation of glutamine show unequivocal effects. A systematic Cochrane review concluded oral glutamine may reduce mucositis, days of opioids and GVHD. Based on two studies, parenteral glutamine may reduce clinical infections and positive cultures. 70 Arginine is a semi-essential amino acid, obtained from dietary sources and by endogenous synthesis via the urea cycle. Under nonstressed conditions, arginine contributes to adequate wound healing, enhanced immune response and stimulation of various anabolic hormones. Arginine is also a unique substrate for the production of nitric oxide. 71 The use of high arginine containing diets in critically ill patients is controversial; the increased nitric oxide production caused by arginine supplementation may lead to increased tissue injury, and trigger cardiovascular collapse in patients with sepsis and systemic inflammation response syndrome. Arginine also appears to increase the inflammatory response and to counteract the reduction of the inflammatory response by n-3 fatty acids. On the other hand, sepsis is an arginine deficient state, and the decreased production of nitric oxide exacerbates the microvascular injury, suggesting benefits of arginine supplementation. Other studies showed that arginine has no adverse effects on haemodynamic effects in patients with septic shock. 64 Some data suggest that giving glutamine and arginine together may be beneficial during intestinal inflammation, in particular on inflammatory response and digestive tract barrier function. 72 Animal studies found an association between arginine, nitric oxide production and GVHD: in vivo administration of human arginase-1 resulted in L-arginine depletion and significant GVHD reduction, 73 and administration of L-arginine after injection of endotoxin blocked nitric oxide production in the intestine. 74 Treatment of GVHD mice with arginine abrogated GVHD-associated enteropathy and reduced lymphocytic infiltration in the intestinal epithelium. 75 Nucleotides have a role in cellular proliferation and immune modulation. They serve as building blocks for DNA, RNA and ATP, and can be newly synthesized or salvaged. Parenteral supplementation of nucleotides leads to increased immune responsiveness, decreased bacterial translocation and fewer episodes of graft rejection. 71 Nucleotides might also act as prebiotics and facilitate the proliferation of beneficial microflora. Another possible effect from nucleotide supplementation is mitigation of endotoxin-induced mucosal damage. This mechanism may lead to reduced bacterial translocation. 71 Glutamine, arginine and nucleotides could have beneficial effects on the prevention or treatment of GVHD, but up to now no human studies on supplementation of these nutrients have been performed.
Probiotics, prebiotics and dietary fibre The normal enteric bacterial flora influence a variety of intestinal functions and have a key role in nutrition, in maintaining integrity of the epithelial barrier and in the development of mucosal immunity. 76 In SCT and GVHD-DT patients, an impaired mucosal barrier resulting from the conditioning regimen and inflammation may lead to increased bacterial endotoxin translocation to the circulation. In most centres, prophylactic antibiotic treatment before and during transplantation is therefore used.
Probiotics are live microbial food supplements with beneficial effects on human health. 77 The rationale behind supplementing probiotic microorganisms is that they alter the composition of the intestinal microflora and improve the mucosal barrier. So far, no studies on probiotics in humans with GVHD have been published. In one study, the use of probiotics in aGVHD in mice was studied. In this study, treatment of recipient mice with L. rhamnosus GG (a probiotics strain) significantly reduced mortality and gave a reduced GVHD score after SCT. 78 However, a problem with probiotics is that no two probiotics are the same. Different species, even different strains, may have vastly different and even contrasting effects. 76 Another important concern regarding probiotics in SCT patients is their potential to induce bacteraemia.
Prebiotics are non-digestible food ingredients, which beneficially affect the host by selectively stimulating the growth and/or activity of one or a limited number of bacteria strains in the colon. Bacteria stimulated by prebiotics have the potential to improve host health. 77 Prebiotic compounds, such as dietary fibre and resistant starches, can be fermented in the colon, producing shortchain fatty acids, which are the primary source of fuel for colonocytes. These short-chain fatty acids may enhance wound healing in the colon. In patients with inflammatory bowel disease, dietary fibre showed clinical benefits because of maintenance of remission and reduction of colonic damage. 79 No studies on probiotics, prebiotics and dietary fibre in SCT or GVHD patients have been published, and guidelines even recommend limited amounts of dietary fibre in patients with GVHD-DT (grade D). 19 For probiotics, no recommendations were found.
DISCUSSION
The aim of this review was to critically appraise the available literature on nutritional assessment, malabsorption, energy and nutrient requirements, and nutritional support in patients with GVHD-DT.
GVHD-DT is a complicated condition with many consequences for nutritional status, resulting in many questions about nutritional support. This review shows that for a lot of topics on nutrition in GVHD-DT, evidence is lacking. Most studies that were discussed in this review involved small patient populations. The lack of proper, well-designed studies in patients with GVHD-DT makes it hard to compare various outcomes. Transplantation procedures, conditioning regimes and (immunosuppressive) treatments are changing continuously.
This review shows that studies on nutritional support in patients after allo-SCT, in particular with GVHD-DT, are scarce. The literature mainly consists of small studies, neither retrospective nor prospective, and expert opinions. Overall, we propose the following recommendations for clinical practise:
Recommendations for monitoring post allo-SCT patients 1. It is crucial to monitor nutritional issues and to assess body weight on a regular basis (at least once a week). 2. Correct measured body weight for the estimated amount of fluid retention, and consider follow-up of the mid upper arm circumference as a marker of nutritional status. 3. Promote oral or enteral nutrition if the digestive and haemostatic function allow, in order to prevent mucosal atrophy in patients with TPN. 4. Assess serum magnesium, 25 OH vitamin D 3 , vitamin B 12 and zinc during the first months after allo-SCT, and supplement if concentrations are below reference values. 5. If micronutrient intake does not meet requirements, supplements containing vitamins, minerals and trace elements at 100% of the recommended daily allowance are recommended, but without iron in order to prevent iron overload. 6. The safety and efficacy of immune-modulating nutrients (glutamine, arginine, nucleotides and n-3 polyunsaturated fatty acids) have not been proven for patients post allo-SCT. 7. Prebiotics and probiotics should be avoided because of the lack of evidence and the probable risk of infectious complications.
Recommendations for nutritional support for patients with GVHD-DT (in addition to above mentioned recommendations)
1. Vitamin D 3 and calcium supplementation is recommended to minimize bone demineralization due to chronic steroid use. 2. In case of exocrine pancreatic insufficiency, consider pancreatic enzyme replacement therapy (B30 000 U of lipase per meal). 3. Measure faecal fat loss, protein-losing enteropathy (stool nitrogen or alpha 1-antitrypsin) and REE in patients with persistent diarrhoea. 4. In cases of severe gastrointestinal failure (diarrhoea 4500 mL/ day), TPN is recommended. 5. Provide at least 1.5 g/kg/day of protein or 1.8-2.5 g/kg/day in patients with protein-losing enteropathy, as well as adequate amounts of energy (REE plus the amount of energy required for physical activity and faecal energy losses). 6. When diarrhoea is o500 mL/day, oral foods can be introduced, for example using a stepwise oral upgrade diet.
These recommendations are composed of conclusions from the available literature. To adequately treat patients with GVHD-DT, more research on micronutrient status, energy and protein requirements, immunonutrition, pancreatic enzyme replacement therapy, and application of citrulline tests is required. Also, there is need for intervention studies on various nutritional support strategies and administration routes in patients with GVHD-DT.
In clinical practice, the optimal timing and amount of oral or enteral nutrition is unclear, and definitions and cutoff points for intestinal failure in GVHD-DT do not exist. Up to now, the amount of diarrhoea is used to classify the severity of GVHD-DT, but it is hard to quantify the amount of diarrhoea in this patient population.
In conclusion, GVHD-DT is associated with malnutrition, malabsorption, and deficiencies of vitamin D, vitamin B 12 , zinc and magnesium. Multidisciplinary treatment for patients with GVHD-DT, by nurses, haematologists, dieticians and nurse practitioners, should include early nutritional assessment, nutritional support and follow-up of micronutrient status.
